BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 13, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 8, 2016
View Archived Issues
Mitsubishi Tanabe profiles pipeline progress of second quarter of fiscal 2016
Read More
Lundbeck updates key developments of third quarter 2016
Read More
AZD-8931 does not improve progression-free survival in wild-type colorectal cancer patients
Read More
NIH award supports TherapyX's testing of IL10-NanoCap
Read More
NICE recommends Eisai's eribulin for breast cancer
Read More
Ascend Biopharmaceuticals reports interim results of phase I/IIa study on ASN-002
Read More
Study finds pharmacokinetic equivalence between Neulasta pegfilgrastim and Mylan/Biocon biosimilar
Read More
FDA accepts BLA for human rabies immunoglobulin
Read More
First-in-human study of Mucosis' SynGEM begins
Read More
GeoVax and ViaMune to codevelop cancer immunotherapy program
Read More
The Medicines Company discontinues development of MDCO-216
Read More
Amgen presents pipeline highlights of third quarter 2016
Read More
Vertex Pharmaceuticals reports positive phase III results on Orkambi
Read More
CHERISH study of Spinraza in later-onset SMA meets primary endpoint
Read More
TGFB1 may be behind coronary artery disease with glatiramer acetate treatment
Read More
FDA grants several orphan drug designations to APX-001
Read More
Scientists develop a new animal model for BBSOAS
Read More
H. Lundbeck patents PDE1 inhibitors
Read More
Guangdong Zhongsheng Pharmaceutical describes thromboxane synthase inhibitors
Read More
Guangzhou Maxinovel Pharmaceuticals develops ALK tyrosine kinase receptor inhibitors
Read More
Shire offers overview of third quarter 2016
Read More